ReleaseWire Connect

Latest Report launch of Bench-top Dental Autoclaves are the equipment sterilization devices used to decontaminate the equipment used during dental procedures. Rise in number of hospital-acquired infections has generated a need of highly advanced sterilization techniques to promote the sterilization of equipment and other tools of medical industry. Increasing prevalence of dental disorder, high demand for sophisticated dental services and favorable government regulations are some of the prominent factors driving the growth of bench-top dental autoclaves market. Recent introduction of Comprehensive Dental Reform Act of 2012 from the U.S. government has enhanced the reimbursement options for dental healthcare services, thereby promoting the growth of dental equipment market. Furthermore, advancement in cosmetic dental procedures and increasing healthcare expenditures are promoting the penetration of bench-top dental autoclave market. On contrary, the high cost of dental autoclave and lack awareness about hygiene across developing regions would limit the growth of market during the forecast period. However, collective efforts from leading companies and government to create awareness about environmental hygiene and decrease in the cost of equipment would eventually reduce the impact of the above restraints during the forecast period.

Vertebral Compression Fracture (VCF) is a medical condition that occur due to the fractures, cracks and collapses in the bone of spinal column. Vertebral compression fractures are most often caused by osteoporosis, which accounts for ~85% of all VCF cases. It can also occur due to trauma, multiple myeloma, metastasis and malignant bone tumors that may cause spine collapse. According to the American Academy of Orthopaedic Surgeons, ~750,000 cases of osteoporosis-related vertebral compression fractures occur in United States alone. The incidence of osteoporosis and VCF cases are increasing the demand for vertebral compression fractures devices in the market. However, approximately two-third of these patients do not opt for diagnosis. This is because they consider back pain as a sign of aging and arthritis. Hence, there is a huge untapped potential in the market due to the large undiagnosed patient base. The market is primarily driven by growing geriatric population, as VCF is more prevalent in people aged 60 or above. Moreover, factors such as short recovery period, low risk of infection and shorter hospital stay would also contribute to the market growth. However, the risk of post-surgical complications i.e., hemorrhage, vertebral posterior element fracture, nerve root irritation and acceleration of osteoporosis might hinder the market growth.

According to the U.S. Food and Drug Administration (FDA), a combination product is defined as, Two or more separate products packaged together in a single package or as a unit and comprised of drug and device products, device and biological products, or biological and drug products. The growing prevalence of chronic diseases among elderly population, creates an inevitable need for effective therapeutic solutions. In light of such need, pharmaceutical and medical device industries now offer Combination products. Growing number of elderly population, increasing healthcare expenditures along with the increasing popularity of point of care treatments, are some of the vital factors that promote the growth of the global Drug-device combination products market. Additionally, active interventions from the NGO and government organizations, along with the increasing demand for minimally invasive surgeries, would eventually propel the market growth during the forecast period. However, high cost of drugs, rising incidences of chronic disease, adverse side effects associated with products and growing technical challenges to deliver drugs would act as a major restraint to the market. Biological therapies and gene therapies are potential target areas for the global drug-device combination products market. The market is supported by newly developed sciences such as nanotechnology, information technology, polymer science, proteomics and genomics.

Non-small cell Lung cancer is the malignant tissue formation in the lung, usually in the cell lining air passage, which is characterized by abnormal cell growth in lung tissue. Globally, lung cancer is one of the leading causes of death since the past several decades. According to the American lung association, the number of deaths due to lung cancer has increased ~3.5% from ~152,156 cases in 1999 to ~157,499 in 2012. Furthermore, it is estimated that 158,040 Americans are would die due to lung cancer by 2015. According to the American Society of cancer, Non small-cell lung cancer accounts for ~85% to 90% of overall lung cancer cases and the trend is expected to grow with the same momentum. Thus, a large patient base of non small-cell lung cancer depicts the unmet need for diagnosis and treatment. It has been observed that non small-cell lung cancer is the most prevalent type of lung cancer commonly caused due to active and passive smoking.

Diagnostic Imaging is a technique used to examine the internal environment of the body. It helps in diagnosis and monitoring the progression of diseases. The evolution of diagnostic imaging techniques, has played a vital role in the development of healthcare industry. The diagnostic imaging market is flourished by innovations, such as ultra-fast and digital devices. It is yet imperative to find better economic alternatives which would help in the early diagnosis of disease. The major factors driving the global diagnostic imaging market are higher incidences of cardiovascular, oncology and other diseases, higher disposable incomes, increasing awareness and education. Rising number of diagnostic centres, hospitals and emergence of ambulatory devices have opened lucrative opportunities in the diagnostic imaging market. However, the high cost of treatment, lack of skilled workforce, and obscure reimbursement scenario across the globe, are likely to restrict the market growth.

Virtual reality is the creation of computer generated simulated virtual environment to provide real-life sensory experience to the person. It creates a highly immersive, visual and three dimensional environment, in which an individual is able to manipulate virtual objects and perform a series of tasks. The environment is either of real or simulated world, in which an individual is able to feel and interact with the objects and characters. Virtual treatment has certain advantages over conventional methods of treatment such as virtual treatment often eliminates the use of drugs and complex invasive surgical procedures for treatment, thus saving the cost and time. The major factors driving the global Virtual reality in healthcare market are; rising incidences of neurological disorders, increasing demand for innovative diagnostic techniques and increasing disease awareness. Moreover, recent advancement in the field of information technology such as computer, laptop, internet connectivity and mobile applications, would further fuel the market growth. However, high cost of treatment, lack of skilled workers and inaccessibility to virtual reality technology in developing economies are likely to hinder the market growth.

Cardiovascular diseases (CVD) are one of the foremost public health challenge across the globe. According to World Organization (WHO) estimate, about 17.5 million people died from cardiovascular diseases in 2012, accounting for 31% of all global deaths. Around one third of CVD deaths take place in the low and middle income countries. By the year 2030, more than 23 million people are likely to die annually from cardiovascular diseases. There is an unmet market need for better diagnostics and therapeutics to prevent the mortality from CVDs. Major factors driving the global Cardiac equipment market are, rising geriatric population along with higher incidence of coronary artery diseases, stroke, heart failure, hypertension and diabetes. Furthermore, unhealthy sedentary lifestyle, smoking tobacco, and the high intake of salt and cholesterol, supplement the developments in this market. However, the high cost of treatment and a stringent regulatory environment, are likely to restrain the market growth.

Stroke occurs due to interruptions in the blood supply to brain, either due to the rupture or blockage of blood vessels, leading to the death of brain cells. Stroke is one of the leading cause of death worldwide, with higher prevalence in the old age population. According to the World Health Organization (WHO), stroke accounts for around 17 million deaths annually. As per the Centres for Disease Control and Prevention (CDC), Stroke leads to 1 out of every 20 deaths costing around $34 billion each year in U.S. Hence, there is an impending need for early diagnostic devices and therapeutics to prevent deaths from stroke. The major factors driving the stroke diagnostics and therapeutics market are large patient pool along with rising aging population. The patients at risk of developing stroke, mainly those suffering from hypertension, atrial fibrillation and coronary heart diseases, would further fuel the market growth. Other factors leading to market growth are rising incidences of diabetes and large number of tobacco users. However, high cost of treatment and lack of transparent reimbursement scenario, are likely to restrict the market growth.

Renal biomarkers help diagnose or identify the patients at risk of developing kidney diseases, by measuring their blood or urine levels. They are commonly released in acute or chronic kidney injuries, which are characterized by the rapid or gradual loss of kidney function resulting into serous clinical implications. There is an impending need for specific and sensitive biomarkers that can identify kidney diseases at the earliest. The early identification helps to take timely preventive steps, before the damage becomes irreversible. The major factors fuelling the global Renal biomarkers market are; increased incidence of kidney diseases, large geriatric population and increasing prevalence of multiple co-morbidities. The market would also gain prominence due to rising incidences of chronic diseases such as diabetes, obesity and hypertension, as these diseases are often associated with the gradual loss of kidney function. Furthermore, increasing investments in research and development will further drive the market, as renal biomarkers are widely used in preclinical and clinical trials, to assess the safety of new drugs. However, lack of transparent reimbursement and regulatory scenario, especially, in the developing countries, is likely to restrain the market.

Global Market Research Report on Blood Testing Technologies Market 2016 is a professional and in-depth complete study on the current state of the Blood Testing Technologies worldwide.